On the surface, this week’s Vera Rubin launch is another major platform moment for Nvidia Corp., as the company maintains a steady drumbeat of artificial intelligence infrastructure innovation. Nvidia is positioning Vera Rubin as a full-stack system designed to improve performance per watt and reduce token costs, with production ramping across a broad global partner base, including cloud and AI infrastructure providers.
Neocloud provider QumulusAI said today that it will starting trading Thursday as a publicly traded company on Nasdaq under the ticker symbol QMLS via a direct listing. For those unfamiliar with the process, the typical initial public offering takes time and requires an investment banker, whereas a direct listing does not create new shares. Instead, existing shareholders sell their shares to the public without an underwriter.
Read More About
QumulusAI’s direct listing: Accelerating the neocloud for enterprise AI
There remains a common misconception that Zoom is a meeting app. Though Zoom Communications Inc. arguably does meetings better than anyone, it has evolved into a broad work platform. Mount Sinai Health System in New York treats Zoom as core infrastructure.
Read More About
Mount Sinai’s Zoom strategy shows why collaboration is now core infrastructure
Couchbase Inc. is trying to solve one of the hardest problems in enterprise artificial intelligence today: turning brittle, chat-style pilots into production-grade agents capable of remembering, reasoning and acting on live operational data. With the launch of its AI Data Plane, the company is betting that the real bottleneck for “agentic” AI isn’t the model — it’s the underlying data architecture.
Read More About
Couchbase’s AI Data Plane aims to turn fragmented data into real enterprise agent memory
Artificial intelligence played a prominent role at this week’s Bio International Convention in San Diego, the largest biotech event with vendors spanning the full ecosystem of companies in this industry. Today in a special address, Kimberly Powell (pictured), vice president and general manager of healthcare and life sciences at Nvidia Corp., made the case that agentic AI is about to do for biotech what it just did for software — and the company’s BioNeMo is the stack that turns generic large language models into working “AI scientists” that are both faster and cheaper to run.